Companies › Iterum Therapeutics, International
1 active drug program in 1 registered trial: 1 Phase 1; Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sulopenem Bacterial penicillin-binding protein inhibitor | UNKNOWN | Phase 1 | Pharmacokinetics After Oral Intake | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07092813 | Sulopenem | Phase 1 | Pharmacokinetics After Oral Intake | Other | Oct 2026 |
General Oncology Gilead Sciences Colgate Palmolive Vaxcyte Zhejiang Raygene Pharmaceuticals
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.